



Alnylam to Webcast Presentations at Upcoming June Investor Conferences

May 29, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 29, 2018-- [Alnylam Pharmaceuticals, Inc.](http://www.alnylam.com) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:

- Bernstein 34th Annual Strategic Decisions Conference on Friday, June 1, 2018 at 9:00 am ET at the Grand Hyatt in New York City
- Jefferies 2018 Global Healthcare Conference on Wednesday, June 6, 2018 at 4:00 pm ET at the Grand Hyatt in New York City
- Goldman Sachs 39th Annual Global Healthcare Conference on Thursday, June 14, 2018 at 9:20 am PT (12:20 pm ET) at the Terranea Resort in Rancho Palos Verdes, California

A live audio webcast of each presentation will be available on the Investors section of the Company's website, www.alnylam.com. A replay will be available on the Alnylam website within 48 hours after each event.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, and hepatic infectious diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform and deep pipeline of investigational medicines, including four product candidates that are in late-stage development. Looking forward, Alnylam will continue to execute on its "Alnylam 2020" strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Alnylam employs over 800 people in the U.S. and Europe and is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at [@Alnylam](https://twitter.com/Alnylam) or on [LinkedIn](https://www.linkedin.com/company/alnylam).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180529005128/en/>

Source: Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

Christine Regan Lindenboom, 617-682-4340
(Investors and Media)

or

Josh Brodsky, 617-551-8276
(Investors)